BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 33081486)

  • 1. PET findings in lymphomatosis and gliomatosis of the brain: a comparison of C-11 methionine PET/CT and F-18 FDG PET/CT.
    Tomura N; Saginoya T; Goto H
    Acta Radiol; 2021 Oct; 62(10):1391-1396. PubMed ID: 33081486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 18F-FDG PET/CT in primary brain lymphoma.
    Albano D; Bosio G; Bertoli M; Giubbini R; Bertagna F
    J Neurooncol; 2018 Feb; 136(3):577-583. PubMed ID: 29147860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of
    Kaste SC; Snyder SE; Metzger ML; Sandlund JT; Howard SC; Krasin M; Shulkin BL
    J Nucl Med; 2017 Mar; 58(3):419-424. PubMed ID: 27609791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative evaluation of
    Norikane T; Mitamura K; Yamamoto Y; Manabe Y; Murao M; Arai-Okuda H; Hatakeyama T; Miyake K; Nishiyama Y
    J Neurooncol; 2024 Jan; 166(1):195-201. PubMed ID: 38160415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PET/CT findings for tumors in the base of the skull: comparison of 18 F-FDG with 11 C-methionine.
    Tomura N; Mizuno Y; Saginoya T
    Acta Radiol; 2016 Mar; 57(3):325-32. PubMed ID: 25795702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 11C-Methionine Positron Emission Tomography/Computed Tomography Versus 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Evaluation of Residual or Recurrent World Health Organization Grades II and III Meningioma After Treatment.
    Tomura N; Saginoya T; Goto H
    J Comput Assist Tomogr; 2018; 42(4):517-521. PubMed ID: 29613985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Role of Dual-Phase FDG PET/CT in the Diagnosis and Follow-Up of Brain Tumors.
    Özütemiz C; Neil EC; Tanwar M; Rubin NT; Ozturk K; Cayci Z
    AJR Am J Roentgenol; 2020 Oct; 215(4):985-996. PubMed ID: 32841063
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparison of F-18 FDG and C-11 methionine PET/CT for the evaluation of recurrent primary brain tumors.
    Tripathi M; Sharma R; Varshney R; Jaimini A; Jain J; Souza MM; Bal J; Pandey S; Kumar N; Mishra AK; Mondal A
    Clin Nucl Med; 2012 Feb; 37(2):158-63. PubMed ID: 22228339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of focal cortical dysplasia and mixed neuronal and glial tumors in pediatric epilepsy patients using 18F-FDG and 11C-methionine pet.
    Phi JH; Paeng JC; Lee HS; Wang KC; Cho BK; Lee JY; Park SH; Lee J; Lee DS; Kim SK
    J Nucl Med; 2010 May; 51(5):728-34. PubMed ID: 20395328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic Value of 68Ga PSMA-11 PET/CT Imaging of Brain Tumors-Preliminary Analysis.
    Sasikumar A; Joy A; Pillai MR; Nanabala R; Anees K M; Jayaprakash PG; Madhavan J; Nair S
    Clin Nucl Med; 2017 Jan; 42(1):e41-e48. PubMed ID: 27846000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stereotactic brain biopsy guided by positron emission tomography (PET) with [F-18]fluorodeoxyglucose and [C-11]methionine.
    Pirotte B; Goldman S; David P; Wikler D; Damhaut P; Vandesteene A; Salmon L; Brotchi J; Levivier M
    Acta Neurochir Suppl; 1997; 68():133-8. PubMed ID: 9233429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation of
    Mitamura K; Yamamoto Y; Norikane T; Hatakeyama T; Okada M; Nishiyama Y
    Ann Nucl Med; 2018 Nov; 32(9):627-633. PubMed ID: 30032455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Combined use of positron emission tomography with (18)F-fluorodeoxyglucose and (11)C-methionine for preoperative evaluation of gliomas].
    Yamaguchi S; Terasaka S; Kobayashi H; Narita T; Hirata K; Shiga S; Usui R; Tanaka S; Kubota K; Murata J; Asaoka K
    No Shinkei Geka; 2010 Jul; 38(7):621-8. PubMed ID: 20628188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical value of ¹¹C-methionine PET/CT in patients with plasma cell malignancy: comparison with ¹⁸F-FDG PET/CT.
    Nakamoto Y; Kurihara K; Nishizawa M; Yamashita K; Nakatani K; Kondo T; Takaori-Kondo A; Togashi K
    Eur J Nucl Med Mol Imaging; 2013 May; 40(5):708-15. PubMed ID: 23340595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ¹¹C-methionine and ¹⁸F-fluorodeoxyglucose positron emission tomography/CT in the evaluation of patients with suspected primary and residual/recurrent gliomas.
    Li DL; Xu YK; Wang QS; Wu HB; Li HS
    Chin Med J (Engl); 2012 Jan; 125(1):91-6. PubMed ID: 22340472
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Morales-Lozano MI; Rodriguez-Otero P; Sancho L; Nuñez-Cordoba JM; Prieto E; Marcos-Jubilar M; Rosales JJ; Alfonso A; Guillen EF; San-Miguel J; Garcia-Velloso MJ
    Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined use of 18F-fluorodeoxyglucose and 11C-methionine in 45 positron emission tomography-guided stereotactic brain biopsies.
    Pirotte B; Goldman S; Massager N; David P; Wikler D; Lipszyc M; Salmon I; Brotchi J; Levivier M
    J Neurosurg; 2004 Sep; 101(3):476-83. PubMed ID: 15352606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 18F-FDG PET/CT in splenic marginal zone lymphoma.
    Albano D; Giubbini R; Bertagna F
    Abdom Radiol (NY); 2018 Oct; 43(10):2721-2727. PubMed ID: 29500652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of 11C-methionine PET and 18F-FDG PET in patients with primary central nervous system lymphoma.
    Kawase Y; Yamamoto Y; Kameyama R; Kawai N; Kudomi N; Nishiyama Y
    Mol Imaging Biol; 2011 Dec; 13(6):1284-9. PubMed ID: 21042866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.